Boston Scientific sells BTG Specialty Pharmaceuticals to SERB for $800M

Boston Scientific announced the sale of its BTG Specialty Pharmaceuticals business to European specialty pharmaceutical group SERB for $800 million, completing the divestiture of non-device assets acquired with BTG.

“Boston Scientific’s sale of the BTG business to European specialty pharmaceutical group SERB for $800 million completes its divestiture of recently acquired non-device assets.”medtechdive.com

• 2 sources
• medtechdive.comZimmer puts up $250M in surgical device deal, Boston Scientific nets $800M in BTG pharma sell-off | MedTech DiveNick Paul TaylorDec 1, 2020
• mddionline.comMedtech in a Minute: Divestitures and M&A, Oh My!Amanda PedersenDec 7, 2020

Summarized from public sources; check the original articles before acting on it.